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ABSTRACT
Background
The prevalence and severity of chronic kidney disease
(CKD) in primary care patients with diabetes or
hypertension is unknown.
Aim
To assess the prevalence and severity of CKD in patients
with diabetes and hypertension; and identify whether





Two Dutch primary health care centres (15 954 enlisted
patients).
Method
Patients, aged ≥25 years, with known diabetes type 2
(n = 471) or hypertension (n = 960), were selected on 1
October 2006. Initial screening uptake rates were
assessed from the electronic patient records, and
patients were invited when blood or urine measurements
were missing. The presence of albuminuria was
determined, glomerular filtration rate estimated, and
clinical characteristics extracted.
Results
Initial screening uptake rates were 93% and 69% for
diabetes and hypertension, respectively, and increased to
97% (n = 455) and 87% (n = 836) after active invitation.
The prevalence of CKD was 28% in diabetes and 21% in
hypertension only. The presence of diabetes was
independently associated with albuminuria (odds ratio
[OR] 4.23; 95% confidence interval [CI] = 2.67 to 6.71),
but not with decreased estimated GFR (eGFR) (OR 0.75;
95% CI = 0.54 to 1.04). Age showed the strongest
association with decreased eGFR (OR 2.73; 95% CI =
2.02 to 3.70).
Conclusion
In primary care, more than one-quarter of patients with
diabetes and about one-fifth of patients with
hypertension have CKD. The high prevalence justifies
longitudinal follow-up in order to evaluate whether
intensified cardiovascular risk management is beneficial
in this primary care population.
Keywords
diabetes; hypertension; kidney disease, chronic;
prevalence; primary care; screening.
INTRODUCTION
Chronic kidney disease (CKD), defined as either
decreased glomerular filtration rate (GFR) or
albuminuria, or both, carries a risk of cardiovascular
morbidity and mortality and progression to end-
stage renal disease.1–3
Diabetes and hypertension are major causes of
CKD.4 Therefore, current international guidelines
recommend yearly screening for CKD in patients with
diabetes or hypertension.5,6 Although the prevalence
of CKD stages 3–5 (defined as estimated GFR
<60 ml/min per 1.73 m2) in the adult primary care
population is estimated to be 5–7%, data on the
prevalence of CKD in high-risk (that is, diabetes and
hypertension) primary care patients are scarce.7,8
Additionally, the prevalent stages of severity and
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current treatment of CKD in primary care patients
with hypertension or diabetes are unknown.
Compliance with screening for CKD by primary
care providers is low.9 Data from 2001 to 2004
revealed that in the Netherlands only 33% of patients
with hypertension or diabetes are screened yearly for
serum creatinine, and only 10% of patients with
diabetes are screened for albuminuria.9 Possibly,
absence of scientific data on the prevalence of CKD
in primary care patients with hypertension or diabetes
may contribute to these low screening uptake rates
and subsequent underdiagnosis and undertreatment.
Therefore, a survey was conducted among primary
care patients that aimed to: assess the prevalence,
severity and current treatment with angiotensin-
converting enzyme (ACE) inhibitors or angiotensin
receptor blockers of CKD in patients with diabetes or
hypertension; and identify whether age, sex,
diabetes, and hypertension are associated with
albuminuria and decreased GFR.
METHOD
Population
Patient data were obtained from two primary
healthcare centres (11 GPs) in Leiden, the Netherlands.
In Dutch primary health care, each inhabitant is
registered with a general practice. The two primary
healthcare centres serve a total population of 15 954.
For each registered patient, diagnoses are coded
according to the International Classification of Primary
Care (ICPC) in an electronic patient record.10 Patients
were selected who were aged ≥25 years with a known
diagnosis of hypertension (ICPC code K86
hypertension uncomplicated or K87 hypertension
complicated) or type 2 diabetes mellitus (ICPC code
T90). Patients with type 1 diabetes, or with type 2
diabetes or hypertension under hospital-based
subspecialty care were excluded.
Design
A cross-sectional survey was started in October
2006, using data in the electronic patient records
compiled by family physicians. For the selected
patients, assessments of serum creatinine and
albumin-to-creatinine ratio in urine (the preferred
measurement for the detection of albuminuria) within
15 months prior to the selection date were extracted.
Next, if no assessments or only one assessment
were present in the electronic patient record, patients
were actively invited by post or telephone to visit the
primary healthcare centre for screening of serum
creatinine and albumin-to-creatinine ratio.
Data were collected on demographic and clinical
characteristics regarding age, sex, duration of
hypertension or diabetes, cardiovascular comorbidity,
blood pressure, fasting plasma glucose, glycosylated
haemoglobin, body mass index (BMI), and waist
circumference. The last available measures within the
previous 15 months were used in the analyses.
Cardiovascular comorbidity was present when at
least one ICPC code for cardiovascular disease was
registered (Table 1).10 Data on current use of ACE
inhibitor, angiotensin receptor blocker, and insulin
were extracted from the electronic patient record.
Measurements
All clinical chemical analyses were performed by
SCAL Medical and Diagnostic Centre, Leiden, the
Netherlands. For the determination of albumin and
creatinine, the Roche Integra 800 (Roche, Basel,
Switzerland) was used. Serum creatinine was
measured enzymatically in 2006 and was not IDMS
(isotope dilution mass spectrometry) calibrated.
Chronic kidney disease
Chronic kidney disease (CKD) was defined in terms
of kidney damage (albuminuria) and decreased
kidney function (decreased estimated glomerular
filtration rate [eGFR]).11 Albuminuria was defined as
an albumin-to-creatinine ratio greater than
2.5 mg/mmol or 3.5 mg/mmol for men and women,
respectively, on at least two occasions.12 Urine
sample data were coded as missing if only one
measurement was present.11 If two (or more)
How this fits in
Chronic kidney disease is an independent risk factor for cardiovascular
morbidity and mortality. The prevalence of chronic kidney disease in primary
care patients with diabetes and hypertension, already at increased
cardiovascular risk, is unknown. This study shows that more than one-quarter
of patients with diabetes and about one-fifth of patients with hypertension have
chronic kidney disease, which justifies intensified cardiovascular risk





K74 Ischaemic heart disease with angina pectoris
K75 Acute myocardial infarction
K76 Ischaemic heart diseases without angina pectoris
K77 Heart failure
K78 Atrial fibrillation
K89 Transient cerebral ischaemia
K90 Stroke/cerebrovascular accident
K91 Atherosclerosis
K92 Peripheral vascular diseases
Table 1. Selected ICPC codes for
cardiovascular comorbidity.
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measurements were present, the most recent sample
was used for analysis of the data.
The eGFR was calculated from the modification of
diet in renal disease (MDRD) equation:
eGFR = 186 × (serum creatinine × 0.0113)–1.154 ×
(age)–0.203 × (0.742 if female),4 where eGFR is
measured in ml/min per 1.73m2, creatinine is in
µmol/L, and age in years.
The stage of CKD was determined by kidney
function and the presence of albuminuria. Stage 1 and
2 required the presence of albuminuria plus eGFR of
≥90 and 60–89 mL/min per 1.73 m2, respectively.
Stage 3, 4, and 5 were defined by an eGFR of 30–59,
15–29, and <15 ml/min per 1.73 m2 (or dialysis) either
with or without albuminuria, respectively.11
Statistical analysis
With regard to the first study objective (prevalence,
severity, and current treatment of CKD), proportions
among patients with hypertension only or with
diabetes were calculated. Statistical differences
between the two groups were calculated by two-
sample Student t-tests for continuous outcomes and
Fisher’s exact tests for dichotomous outcomes.
Because patients with a double diagnosis of
diabetes and hypertension have perhaps only been
registered as having diabetes (ICPC T90) and not as
having hypertension (ICPC K86 or K87), it was
decided not to split the diabetes group into those
with and without hypertension in the main analysis.
With regard to the second study objective
(association of age, sex, diabetes, and hypertension
with CKD), logistic regression models for albuminuria
(CKD stage 1 and 2) and decreased eGFR (CKD
stage 3, 4 and 5), respectively, were used.
Dichotomised values were used for age (≤65 versus
>65 years) and blood pressure (systolic blood
pressure ≤140 versus >140 mmHg). The association
of age with CKD was adjusted for sex and vice versa.
The association of diabetes with CKD was adjusted
for age, sex, and hypertension, and the association
of hypertension with CKD adjusted for age, sex, and
diabetes. All analyses were carried out with Stata
(version 10.0 StataCorp).
RESULTS
The two primary healthcare centres had 10 740
patients aged ≥25 years (Tables 2 and 3). There were
471 patients (4.4%) registered with type 2 diabetes
and 960 patients (8.9%) with hypertension only. Data
on serum creatinine and albumin-to-creatinine ratio
within 15 months prior to the selection date were
initially available for 439 (93%) and 666 (69%)
patients, respectively. After active invitation for
screening of serum creatinine and albumin-to-
creatinine ratio, data were available for 455 (97%) and
836 (87%) patients, respectively (Figure 1). Compared
to patients with hypertension only who attended
screening, the 13% of patients with hypertension only
who did not attend screening for CKD had similar age
(P = 0.99) and sex (P = 0.21), but more often had
cardiovascular comorbidity (28% versus 19%,
P = 0.024) and less often used ACE inhibitors or
angiotensin receptor blockers (41% versus 54%,
P = 0.009).
Demographic and clinical characteristics are listed
in Table 4. The group of patients with diabetes had a
mean age of 63 years; 51% were female. Of all
patients with diabetes, 53% had registered comorbid
hypertension. Patients with hypertension only had a
mean age of 61 years; 57% were female.
Cardiovascular comorbidity was more prevalent in
patients with diabetes than in patients with
hypertension only: 30% versus 19% (P<0.001).
Patients with diabetes had a higher BMI and waist
circumference, but lower blood pressure than
patients with hypertension only. Serum total
cholesterol and low-density lipoprotein cholesterol
levels were higher for patients with hypertension only
than for patients with diabetes. About half of all
patients in both groups used ACE inhibitors or
angiotensin receptor blockers.
Chronic kidney disease
Table 5 shows the prevalence of albuminuria, eGFR
rate strata, and CKD stages for the diabetes-only and
hypertension-only groups. Albuminuria was present in
13.6% of the diabetes group and 3.6% of the
Age band, years Male, n (%) Female, n (%)
0–24 2653 (33.7) 2561 (31.7)
25–44 2405 (30.5) 2458 (30.4)
45–64 2179 (27.7) 2276 (28.2)
65–74 441 (5.6) 426 (5.3)
≥75 199 (2.5) 356 (4.4)
Total 7877 8077
Table 2. Age–sex profile of the study
population. Percentages reflect
proportion across the columns.
Age band, years Sample, n Diabetes, n (%) Hypertension, n (%)
0–24 5214 9 (0.17) 7 (0.13)
25–44 4863 50 (1.0) 123 (2.5)
45–64 4455 311 (7.0) 738 (16.6)
65–74 867 112 (12.9) 272 (31.4)
≥75 555 119 (19.8) 258 (46.5)
Total 15 954 601 (3.8) 1 398 (8.8)
Table 3. Age-diabetes and age-hypertension profile of the
study population.
Original Papers
hypertension only group. The prevalence of CKD
(stage 1–5) was 27.5% in the diabetes group and
21.1% in the hypertension-only group. Stage 3 was
the most prevalent stage for both groups: 17.5% and
17.1% respectively.
Of the 62 diabetes patients with albuminuria, 47
(76%) were currently treated with ACE inhibitor or
angiotensin receptor blocker, compared to 29 of 30
(97%) patients treated for albuminuria in the
hypertension-only group. Of all 92 patients with
albuminuria, 16 (17%) were not treated with ACE
inhibitor or angiotensin receptor blocker.
Associations with kidney damage
(albuminuria)
Figure 2 displays associations of age, sex, diabetes,
and hypertension characteristics with albuminuria.
Diabetes had the strongest association with
albuminuria; of all patients with diabetes, 13.6% had
albuminuria compared to 3.6% of patients without
diabetes (adjusted odds ratio [OR] 4.23; 95%
confidence interval [CI] = 2.67 to 6.71).
Patients aged >65 years more often had albuminuria
than patients aged ≤65 years (11.2% versus 4.9%;
adjusted OR 2.53; 95% CI = 1.64 to 3.89), and patients
with hypertension more often than patients without
hypertension (8.8% versus 5.7%; adjusted OR 1.63;
95% CI = 1.04 to 2.58). The presence of albuminuria
was similar for men and women (7.9% versus 6.5 %;
adjusted OR 1.35; 95% CI = 0.88 to 2.08).
Associations with decreased kidney function
(eGFR<60 ml/min per 1.73 m2)
Figure 3 displays associations of demographic and
clinical characteristics with decreased kidney
function. Decreased eGFR was more present in older
than younger patients: 25.8% in patients aged
>65 years and 10.9% in patients aged ≤65 years
(adjusted OR 2.73; 95% CI = 2.02 to 3.70). Men had
decreased eGFR less often than women: 11.4%
versus 20.2% (adjusted OR 0.54; 95% CI = 0.39 to
0.74). There were no statistically significant
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Population aged ≥25 years
2 Primary healthcare centres
n = 10 740
Diabetes mellitus
n = 592 (5.5%)
Hypertension
n = 1391 (13%)
Subspeciality care
n = 78





(included in other arm)
n = 248














Figure 1. Flow diagram of
selection procedure.
Diabetes mellitus Hypertension only
type 2, n = 455 n = 836 P-valuea
Age, years, mean (SD) 63 (13) 61 (12) 0.004
Female sex, n (%) 233 (51) 479 (57) 0.040
Duration diagnosis, years, mean (SD) 7.2 (5.4) 6.5 (4.8) 0.027
Cardiovascular comorbidityb, n (%) 137 (30) 161 (19) <0.001
Diabetes with hypertension, n (%) 239 (53) n/a n/a
Body Mass index, kg/m2, mean (SD) 29.7 (5.5) 27.7 (4.5) <0.001
Waist circumference, cm, mean (SD)
Women 100 (12) 93 (13) <0.001
Men 104 (14) 101 (11) 0.008
Actual blood pressure, mmHg, mean (SD)
Systolic 139 (18) 144 (16) <0.001
Diastolic 81 (8) 84 (9) <0.001
Fasting plasma glucose, mmol/l, mean (SD) 7.2 (2.0) 5.3 (0.7) <0.001
Glycosylated hemoglobin, % (SD) 6.7 (1.0) 5.5 (0.4) <0.001
Total cholesterol, mmol/l, mean (SD) 4.6 (1.1) 5.5 (1.1) <0.001
LDL cholesterol, mmol/l, mean (SD) 2.5 (0.9) 3.3 (1.0) <0.001
Medication, n (%)
ACEi/ARB 228 (50) 452 (54) 0.18
Insulin 88 (19) n/a n/a
No glucose lowering drugs 132 (29) n/a n/a
ACEi = Angiotensin Converting Enzyme inhibitor. ARB = Angiotensin receptor blocker. LDL =
Low density lipoprotein. SD = standard deviation. at-tests and Fisher’s exact tests for
continuous and dichotomous outcomes, respectively. bOne or more International Classification
of Primary Care (ICPC) codes for cardiovascular diseases (see Table 1).
Table 4. Demographic and clinical characteristics of primary
care patients aged ≥25 years with diabetes mellitus type 2
or with hypertension only.
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differences in decreased eGFR between patients
with and without diabetes (14.1% versus 17.5%,
respectively; adjusted OR 0.75; 95% CI = 0.54 to
1.04) and between patients with and without
hypertension (16.7% versus 15.4%, respectively;
adjusted OR 1.10; 95% CI = 0.82 to 1.48).
DISCUSSION
Summary of main findings
A cross-sectional survey was conducted among
primary care patients with diabetes and hypertension
in order to assess the prevalence and severity of
CKD. The prevalence of CKD was 28% in patients
with diabetes and 21% in patients with hypertension
only; CKD stage 3 was the most prevalent stage
(17%) in both patient groups. The presence of
diabetes was independently associated with
albuminuria but not with decreased eGFR.
Strengths and limitations of the study
To the authors’ knowledge, this is the first study that
evaluates the prevalence and severity of CKD in
primary care patients with diabetes or hypertension
with the use of both serum creatinine assessments
(to estimate GFR) and urine albumin excretion (to
determine albuminuria). Screening uptake rates are
high, providing valid prevalence estimates. The
prevalence of stage 3 is greater than that of stages 1
and 2. This is due to the definition of stage 1 and 2
requiring evidence of kidney damage (albuminuria),
which is not required for stage 3.
Some methodological issues need particular
attention. First, the study is limited by its cross-
sectional design. There is no information available
about the course of CKD, and factors that may
predict rapid worsening of albuminuria or kidney
function and subsequent cardiovascular events.
Moreover, due to the relatively small samples in this
study, associations between different severity levels
(of both diabetes and hypertension) and CKD have
not been studied. Follow-up data are required on
how the identified associations with albuminuria
(diabetes, age, and high current blood pressure) and
decreased eGFR (age and sex) predict
cardiovascular and renal outcome. Second, the
study was performed in a limited number of primary
healthcare centres, which are possibly not
representative of all Dutch family physicians. The
practices have affiliations with the Leiden University
Medical Centre, which reflects increased awareness
of GPs and staff of obtaining valid data and high
screening uptake rates. However, this study shows
that adherence and commitment to management
guidelines with regard to diabetes, hypertension, and
screening for CKD can lead to remarkably high
screening uptake rates and a high proportion treated
Diabetes mellitus Hypertension only
type 2, n = 455 n = 836 P-valuea
Albuminuriab, n (%) 62 (13.6) 30 (3.6) <0.001
eGFR, n (%) <0.001
≥90 ml/min/1.73 m2 137 (30) 146 (18)
60–89 238 (52) 540 (65)
45–59 64 (14) 128 (15)
30–44 14 (3.1) 18 (2.2)
15–29 2 (0.4) 4 (0.5)
<15 0 0
Chronic kidney disease, n (%) <0.001
Stage 1: eGFR ≥90 + albuminuria 21 (4.6) 2 (0.2)
Stage 2: eGFR 60–89 + albuminuria 25 (5.5) 24 (2.9)
Stage 3a: eGFR 45–59 64 (14.0) 128 (15.3)
Stage 3b: eGFR 30–44 14 (3.1) 18 (2.2)
Stage 4: eGFR 15–29 2 (0.4) 4 (0.5)
Stage 5: eGFR <15 or 0 0
kidney replacement therapy
Total chronic kidney disease, n (%)
(stage 1–5) 125 (27.5) 176 (21.1)
eGFR = estimated glomerular filtration rate. aFisher’s exact tests. bAlbumin-to-creatinine ratio
>2.5 mg/mmol for men, >3.5 mg/mmol for women on at least two occasions.
Table 5. Prevalence of albuminuria, estimated glomerular
filtration rate (eGFR) and stages of chronic kidney disease.
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P<0.001 P = 0.082
Figure 2. Proportions of patients with albuminuria. Error bars indicate standard error of
the mean. P-values were derived from the logistic regression models.
Figure 3. Proportions of patients with decreased estimated glomerular filtration rate (eGFR).
Error bars indicate standard error of the mean. P-values were derived from the logistic
regression models.
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with ACE inhibitors/angiotensin receptor blockers in
family practice.
Third, the study used the urine albumin-to-
creatinine ratio as a measure of kidney damage.
However, other measures are available such as urine
sediment abnormalities and abnormal findings on
imaging studies. Therefore the prevalence estimate
of CKD stage 1–2 might be an underestimation,
because some cases were missed.
Comparison with existing literature
This study evaluates the prevalence and severity of
CKD in primary care patients with diabetes or
hypertension with the use of assessments of serum
creatinine as well as urine albumin. Some studies
reported the prevalence of CKD stage 3–5, but not
stage 1–2 (albuminuria), in high-risk primary care
patients.13,14 Others assessed the prevalence of CKD
in the general population was about 5–7%.7,8
However, the validity of these prevalence estimates
was impaired by incomplete eGFR and albuminuria
data.7,8 In this study, the focus was on high-risk
primary care patients (that is, with diabetes or
hypertension) in order to identify the proportion of
people with CKD in candidate risk groups.1,15 In
patients with hypertension only, the screening uptake
rate was lower (87%) than in patients with diabetes
(97%). The patients with hypertension who did not
attend screening had more cardiovascular
comorbidity and used fewer ACE inhibitors and
angiotensin receptor blockers. Therefore, the study
finding of 21% CKD in patients with hypertension
only might be an underestimation of the actual
prevalence, since CKD is likely to be highly prevalent
in the non-responders with cardiovascular
comorbidity and possible undertreatment.
The definition and classification of CKD is made in
relation to kidney damage (albuminuria) and
decreased kidney function (GFR estimated by the
MDRD formula). The distinction between kidney
damage and decreased kidney function is important,
because prevalence and risk management are
different. The overall prevalence of albuminuria in the
present study population was about 7%. Albuminuria
was much more prevalent in patients with diabetes
(14%) than in patients with hypertension only (4%).
Age and high systolic blood pressure were also
associated with albuminuria. Since albuminuria
predicts cardiovascular events, albuminuria is a
guide to treatment with ACE inhibitors or angiotensin
receptor blockers.4,16
There appears to be some progress in the use of
ACE inhibitors/angiotensin receptor blockers in
primary care diabetes patients: in the present study
sample three-quarter of patients with diabetes and
albuminuria were treated with ACE
inhibitors/angiotensin receptor blockers compared
with about one-third found in previous research.17
However, there is still room for improvement, not only
regarding treatment of albuminuria with ACE
inhibitors/angiotensin receptor blockers, but also
regarding treatment of patients with diabetes and
hypertension with antihypertensive medication to
prevent CKD and cardiovascular disease.17
The prevalence of decreased kidney function (CKD
stage 3–5) was 18%. In contrast to the association
with albuminuria, diabetes and high systolic blood
pressure were not associated with a decreased
estimated GFR. However, statistically significant
associations with decreased kidney function were
found for age and sex. It is well recognised that
kidney function declines with age, but decreased
eGFR in older patients does not always reflect kidney
disease and increased cardiovascular risk.18,19
Recent data show that cardiovascular morbidity
and mortality in an older population aged ≥70 years
was only increased in eGFR levels below
50 ml/min per 1.73 m2, but not in levels between 50
and 60 ml/min per 1.73 m.2,20 Cardiovascular
management in older patients with decreased eGFR
may, therefore, differ from cardiovascular
management in younger patients with impaired renal
function.21
Although the beneficial role of ACE
inhibitors/angiotensin receptor blockers in non-
proteinuric kidney disease is less well established,4
there are several reasons that justify identification,
close follow-up, and intensified cardiovascular risk
management of high-risk patients with decreased
kidney function. First, decreased GFR is
independently associated with the risk of death and
cardiovascular events in young and middle-aged
individuals.2,3,22
Second, several adverse pathophysiological
consequences such as anaemia,
hyperphosphataemia, vitamin D deficiency, and
hyperparathyroidism may need treatment or referral.
Third, identification of decreased kidney function
allows better dosing of drugs excreted by the kidney
and avoidance of nephrotoxic drugs such as non-
steroidal anti-inflammatory drugs.
Implications for future research
To conclude, this study adds knowledge about the
prevalence of CKD in high-risk patients. In the Dutch
university-affiliated primary care centres, more than
one-quarter of patients with diabetes and about one-
fifth of patients with hypertension have CKD. This
high prevalence justifies longitudinal follow-up
research in order to evaluate whether repeated
measurements for CKD and intensified targeted
cardiovascular risk management are beneficial in this
889
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primary care population that is already at increased
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